MedTrace Logo

Double-Blind Study of Topical WBI-1001 Cream on Patients With Psoriasis

NCT00830817 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2009-01-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate primarily the safety and tolerability and secondarily the efficacy of topically applied WBI-1001 cream in patients with mild to moderate psoriasis. Double-blind, randomized, placebo controlled study of 36 patients, treated for 28 days plus a 7 day follow-up.in which the patients were divided into six cohorts: Cohort 1 at 0.5% QD;Cohort 2 at 0.5% BID; Cohort 3 at 1.0% QD; Cohort 4 at 1.0% BID; Cohort 5 at 2.0% QD; Cohort 6 at 2.0% BID.Efficacy assessed by PGA,target lesion assessment and BSA. Safety assessed through vital signs, ECG, AEs and Plasma PK via Cmin, Cmax,Tmax and AUCo-t.

Conditions

Sponsors & Collaborators

  • Welichem Biotech Inc.

    lead INDUSTRY

Principal Investigators

  • John m Webster, PhD, D.Sc. · Welichem Biotech Inc.

  • Liren Tang, Ph.D · Welichem Biotech Inc.

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-04-30
Completion
2008-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00830817 on ClinicalTrials.gov